Literature DB >> 22882089

Angiogenic factors in maternal circulation and preeclampsia with or without fetal growth restriction.

Lars J Vatten1, Bjørn O Åsvold, Anne Eskild.   

Abstract

OBJECTIVE: To study associations of placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt-1) in maternal circulation with the risk of preeclampsia with and without fetal growth restriction.
DESIGN: Nested case-control study.
SETTING: A cohort of 29 948 pregnant women in Norway. SAMPLE: Cases were identified through linkage to the Medical Birth Registry of Norway. We selected 69 preterm and 36 term preeclampsia cases with delivery of a small-for-gestational-age (SGA) infant, 83 preterm and 154 term preeclampsia cases without SGA delivery, and 384 normotensive controls.
METHODS: We measured PlGF and sFlt-1 in maternal serum samples from each trimester. MAIN OUTCOME MEASURES: Odds ratios of preeclampsia subtypes by tertile categories of PlGF and sFlt-1.
RESULTS: Low (lowest third) PlGF and sFlt-1 levels in the first trimester, and low (lowest third) increase in PlGF and strong (highest third) increase in sFlt-1 from first to second trimester were associated with increased risk of preterm preeclampsia, both with and without SGA offspring. For term preeclampsia with SGA offspring, the associations were similar to the findings for preterm preeclampsia. For term preeclampsia without SGA offspring, low increase in PlGF from first to second trimester and high sFlt-1 in the third trimester were associated with increased risk.
CONCLUSIONS: Low PlGF and high sFlt-1 levels in maternal circulation are associated with subsequent development of preeclampsia, regardless of whether fetal growth is affected or not. For term preeclampsia without fetal growth restriction, the imbalance in angiogenic factors seems to appear later in pregnancy than for preterm preeclampsia.
© 2012 The Authors Acta Obstetricia et Gynecologica Scandinavica© 2012 Nordic Federation of Societies of Obstetrics and Gynecology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22882089     DOI: 10.1111/j.1600-0412.2012.01516.x

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  13 in total

1.  The role of angiogenic markers in adverse perinatal outcomes: fresh versus frozen embryo transfers.

Authors:  Irene Woo; Yen Chan; Intira Sriprasert; Kristin Louie; Sue Ingles; Frank Stanczyk; Lynda K McGinnis; Karine Chung
Journal:  J Assist Reprod Genet       Date:  2017-09-04       Impact factor: 3.412

Review 2.  Role of the fetoplacental endothelium in fetal growth restriction with abnormal umbilical artery Doppler velocimetry.

Authors:  Emily J Su
Journal:  Am J Obstet Gynecol       Date:  2015-10       Impact factor: 8.661

3.  Maternal plasma angiogenic index-1 (placental growth factor/soluble vascular endothelial growth factor receptor-1) is a biomarker for the burden of placental lesions consistent with uteroplacental underperfusion: a longitudinal case-cohort study.

Authors:  Steven J Korzeniewski; Roberto Romero; Tinnakorn Chaiworapongsa; Piya Chaemsaithong; Chong Jai Kim; Yeon Mee Kim; Jung-Sun Kim; Bo Hyun Yoon; Sonia S Hassan; Lami Yeo
Journal:  Am J Obstet Gynecol       Date:  2015-12-11       Impact factor: 8.661

4.  The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Amy E Whitten; Steven J Korzeniewski; Piya Chaemsaithong; Edgar Hernandez-Andrade; Lami Yeo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2016

5.  Biochemical tests of placental function versus ultrasound assessment of fetal size for stillbirth and small-for-gestational-age infants.

Authors:  Alexander Ep Heazell; Dexter Jl Hayes; Melissa Whitworth; Yemisi Takwoingi; Susan E Bayliss; Clare Davenport
Journal:  Cochrane Database Syst Rev       Date:  2019-05-14

6.  In-vitro study of the effect of anti-hypertensive drugs on placental hormones and angiogenic proteins synthesis in pre-eclampsia.

Authors:  Subrata Gangooly; Shanthi Muttukrishna; Eric Jauniaux
Journal:  PLoS One       Date:  2014-09-24       Impact factor: 3.240

7.  Placental weight in the first pregnancy and risk for preeclampsia in the second pregnancy: A population-based study of 186 859 women.

Authors:  Johanne Dypvik; Sandra Larsen; Camilla Haavaldsen; Anne M Jukic; Lars J Vatten; Anne Eskild
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2017-05-17       Impact factor: 2.435

8.  Placental Growth Factor Reduces Blood Pressure in a Uteroplacental Ischemia Model of Preeclampsia in Nonhuman Primates.

Authors:  Angela Makris; Kristen R Yeung; Shirlene M Lim; Neroli Sunderland; Scott Heffernan; John F Thompson; Jim Iliopoulos; Murray C Killingsworth; Jim Yong; Bei Xu; Robert F Ogle; Ravi Thadhani; S Ananth Karumanchi; Annemarie Hennessy
Journal:  Hypertension       Date:  2016-04-18       Impact factor: 10.190

9.  Does the Biological Response to Fetal Hypoxia Involve Angiogenesis, Placental Enlargement and Preeclampsia?

Authors:  Anne Eskild; Ellen Marie Strøm-Roum; Camilla Haavaldsen
Journal:  Paediatr Perinat Epidemiol       Date:  2016-05       Impact factor: 3.980

Review 10.  Pre-eclampsia: its pathogenesis and pathophysiolgy.

Authors:  P Gathiram; J Moodley
Journal:  Cardiovasc J Afr       Date:  2016 Mar-Apr       Impact factor: 1.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.